ポリケタル微粒子で結合された原産薬の延長放出
Shutao Guo1, Yoshiyuki Nakagawa1, Aoune Barhoumi1
1Laboratory for Biomaterials and Drug Delivery, Division of Critical Care Medicine, Children's Hospital Boston, Harvard Medical School , 300 Longwood Avenue, Boston, Massachusetts 02115, United States.
Journal of the American Chemical Society
|May 6, 2016
まとめ
研究者らは,長期間作用する高分子量ポリケタル薬の結合体を開発した. 生物分解性の高い バイオコンパティブルな微粒子は 長期にわたる 酸性反応薬の放出を可能にし 慢性疾患の治療に 有望な効果を示しています
科学分野:
- 生物医学工学
- ポリマー化学
- 薬物投与システム
背景:
- ポリケタルは生物分解性,生物相容性,および生物医学的な用途のためのpH感度を提供します.
- 高分子量ポリケタルを合成し,微粒子の配方から持続的な薬剤の放出を達成することは困難です.
研究 の 目的:
- 新しいモノマーを用いて高分子量ポリケタル製薬を合成する.
- 薬剤を長期にわたって放出する微粒子の配列を開発する.
主な方法:
- 添加ポリメリゼーションのための二イソプロペニルエーサーモノマーを合成した.
- エストラディオール-ポリケタル結合微粒子が作られ,薬物の負荷が高い.
- 異なるpH条件とPLGAの併用でエストラディオルの放出運動を調査した.
主要な成果:
- 高分子量ポリケタル-エストラディオルの合成を達成した.
- 微粒子は高い薬物負荷と 顕著に延長されたエストラディオール放出を示した.
- エストラディオルの放出は酸性で,低 pH で加速した.
- 微粒子に対する良性組織反応を示した.
結論:
- ポリケタル製薬コンジュガートは,長期間作用する薬剤の投与のための有効な戦略です.
- 開発された微粒子は,持続的な治療レベルを必要とする慢性疾患の治療に適しています.
- アシド反応性放出は,調節可能な薬物投与プロファイルを提供します.
関連する概念動画
Site-Targeted Drug Delivery Systems: Polymeric Carriers
103
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
103
Modified-Release Drug Delivery Systems: Rate-Programmed II
74
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
74
Oral Drug Delivery Systems: Delayed-Release Systems
125
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
125
Modified-Release Drug Delivery Systems: Drug Release Characteristics
157
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
157
Modified-Release Drug Delivery Systems: Classification
229
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
229
Modified-Release Drug Delivery Systems: Site-Targeted
91
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
91


